KEY FEATURES
Full Name | Fibroblast Growth Factor 1, Acidic |
---|---|
Synonym | ECGF; AFGF; ECGFA; ECGFB; FGF-Alpha; FGFA; HBGF1; ECGFB; HBGF1; Acidic Fibroblast Growth Factor; heparin-binding growth factor 1; Endothelial Cell Growth Factor, Beta |
Assay Type | Sandwich |
Reactivity | Human |
Range | 15.6-1000pg/mL |
Sensitivity | 6.5pg/mL |
Sample Type | Serum,plasma and other biological fluids |
Sample Volume | 100μL |
Detection Wavelength | OD450 |
Transportation Temperature | 2-8°C |
Specificity | The kit detected Human FGF1 in the samples and no significant cross-species reactions were found |
Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human FGF1. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human FGF1 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human FGF1, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human FGF1. You can calculate the concentration of Human FGF1 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
Components | Specifications | Storage and Notes |
---|---|---|
Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human FGF1 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
Intra-assay Precision | Inter-assay Precision | |||||
---|---|---|---|---|---|---|
Sample | 1 | 2 | 3 | 1 | 2 | 3 |
n | 20 | 20 | 20 | 20 | 20 | 20 |
Mean (pg/mL) | 52.13 | 113.31 | 445.98 | 56.4 | 121.06 | 487.97 |
Standard deviation | 3.52 | 4.82 | 19.76 | 2.94 | 5.63 | 18.59 |
CV(%) | 6.76 | 4.25 | 4.43 | 5.22 | 4.65 | 3.81 |
RECOVERY
The recovery of Human FGF1 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
Sample Type | Range (%) | Average Recovery (%) |
---|---|---|
Serum(n=8) | 90-106 | 97 |
EDTA plasma (n=8) | 91-104 | 98 |
Cell culture media (n=8) | 90-103 | 96 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human FGF1 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with FGF4 ELISA Kits
SHH ELISA Kit | publications with FGF4 and SHH |
SOX2 ELISA Kit | publications with FGF4 and SOX2 |
FGFR2 ELISA Kit | publications with FGF4 and FGFR2 |
FGFR1 ELISA Kit | publications with FGF4 and FGFR1 |
CTNNB1 ELISA Kit | publications with FGF4 and CTNNB1 |
FGFR3 ELISA Kit | publications with FGF4 and FGFR3 |
FGFR4 ELISA Kit | publications with FGF4 and FGFR4 |
MSX1 ELISA Kit | publications with FGF4 and MSX1 |
LEF1 ELISA Kit | publications with FGF4 and LEF1 |
GREM1 ELISA Kit | publications with FGF4 and GREM1 |
Pathways associated with FGF4 ELISA Kit
Activated Point Mutants Of FGFR2 Pathway | Activated Point Mutants Of FGFR2 Pathway |
Adaptive Immune System Pathway | Adaptive Immune System Pathway |
Constitutive PI3K/AKT Signaling In Cancer Pathway | Constitutive PI3K/AKT Signaling In Cancer Pathway |
DAP12 Interactions Pathway | DAP12 Interactions Pathway |
DAP12 Signaling Pathway | DAP12 Signaling Pathway |
Disease Pathway | Disease Pathway |
Downstream Signal Transduction Pathway | Downstream Signal Transduction Pathway |
Downstream Signaling Events Of B Cell Receptor (BCR) Pathway | Downstream Signaling Events Of B Cell Receptor (BCR) Pathway |
Downstream Signaling Of Activated FGFR Pathway | Downstream Signaling Of Activated FGFR Pathway |
FGFR Ligand Binding And Activation Pathway | FGFR Ligand Binding And Activation Pathway |
Diseases associated with FGF4 ELISA Kit
Skin Diseases | publications with FGF4 and Skin Diseases |
Breast Neoplasms | publications with FGF4 and Breast Neoplasms |
Disease Models, Animal | publications with FGF4 and Disease Models, Animal |
Cardiovascular Diseases | publications with FGF4 and Cardiovascular Diseases |
Neoplasms, Experimental | publications with FGF4 and Neoplasms, Experimental |
Neoplasm Metastasis | publications with FGF4 and Neoplasm Metastasis |
Neovascularization, Pathologic | publications with FGF4 and Neovascularization, Pathologic |
Nervous System Diseases | publications with FGF4 and Nervous System Diseases |
Brain Diseases | publications with FGF4 and Brain Diseases |
Necrosis | publications with FGF4 and Necrosis |
Organs/Tissues associated with FGF4 ELISA Kit
Embryonic Tissue | publications with FGF4 and Embryonic Tissue |
Testis | publications with FGF4 and Testis |